Selaginella tamariscina water extract inhibits receptor activator for the nuclear factor-κB ligand-induced osteoclast differentiation by blocking mitogen-activated protein kinase and NF-κB signaling

Ki-Shuk Shim*, Ju-Seop Kang**, Min-Ho Lee, Jin Yeul Ma

KM-Based Herbal Drug Research Group, Korea Institute of Oriental Medicine, Daejeon 305-811, Departments of *Pharmacology and Clinical Pharmacology Laboratory, and **Internal Medicine, College of Medicine, Hanyang Biomedical Research Institute, Hanyang University, Seoul 133-791, Republic of Korea

Background: Selaginella tamariscina has been traditionally used in Korea for treating hematochezia, hematuria, and prolapse of the anus. The aim of this study was to evaluate the inhibitory effect of Selaginella tamariscina water extract (ST-WE) on osteoclast differentiation, and to determine the underlying molecular mechanism. Materials and Methods: RAW264.7 cells were used as a model to examine receptor activator for the nuclear factor-κB ligand (RANKL)-induced osteoclast differentiation. Expression of osteoclastic genes and transcription factors was evaluated by real-time quantitative polymerase chain reaction (QPCR). Activation of the mitogen-activated protein kinases, extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, and NF-κB were determined by Western blot analysis. Results: ST-WE significantly inhibited RANKL-induced tartrate-resistant acid phosphatase (TRAP) activity and formation of multinucleated osteoclasts in RAW264.7 cells. ST-WE also significantly inhibited the RANKL-induced mRNA expression of TRAP, cathepsin K, and the d2 isofrom of vacuolar ATPase V(0) domain (ATPv0d2) gene. In addition, ST-WE inhibited the RANKL-induced phosphorylation of ERK, JNK, and p38, phosphorylation of I-κB, and NF-κB p65, and the expression of transcription factors c-fos, Fra-2, and nuclear factor of activated T cells 1. Furthermore, ST inhibited the bone resorptive activity of osteoclasts. Conclusion: ST-WE might have beneficial effects on bone disease by inhibiting osteoclastogenesis and osteoclastic activity.

Key words: Osteoclast differentiation, RAW264.7 cells, receptor activator for nuclear factor-κB ligand, Selaginella tamariscina

INTRODUCTION

Bone remodeling is a homeostatic process that replaces the degradation of old bone with the formation of new bone. This is necessary for the maintenance of bone microstructure and mineral homeostasis in the body.[1] Defects in osteoclastogenesis, increased bone resorption, or the absence of functional osteoclasts causes an imbalance in bone remodeling that might result in various bone diseases, including osteoporosis, osteopetrosis, and rheumatoid arthritis.[2] Therefore, in bone research, it has been suggested that targeting the regulation of osteoclast differentiation and/or osteoclast activation could be a useful approach for developing therapeutic drugs for bone diseases.[3]

Osteoclasts are exclusively bone-resorbing multinuclear cells. They differentiate from the monocyte/macrophage lineage of hematopoietic stem cells in the presence of receptor activator for nuclear factor-κB (NF-κB) ligand (RANKL).[4] RANKL plays a key role in the efficiency of osteoclast differentiation and activation. An interaction between RANKL and its receptor, RANK, triggers the recruitment of tumor necrosis factor receptor-associated I-κB, and NF-κB p65, and the expression of transcription factors c-fos, Fra-2, and nuclear factor of activated T cells 1. Furthermore, ST inhibited the bone resorptive activity of osteoclasts. Conclusion: ST-WE might have beneficial effects on bone disease by inhibiting osteoclastogenesis and osteoclastic activity.

Key words: Osteoclast differentiation, RAW264.7 cells, receptor activator for nuclear factor-κB ligand, Selaginella tamariscina

INTRODUCTION

Bone remodeling is a homeostatic process that replaces the degradation of old bone with the formation of new bone. This is necessary for the maintenance of bone microstructure and mineral homeostasis in the body.[1] Defects in osteoclastogenesis, increased bone resorption, or the absence of functional osteoclasts causes an imbalance in bone remodeling that might result in various bone diseases, including osteoporosis, osteopetrosis, and rheumatoid arthritis.[2] Therefore, in bone research, it has been suggested that targeting the regulation of osteoclast differentiation and/or osteoclast activation could be a useful approach for developing therapeutic drugs for bone diseases.[3]

Osteoclasts are exclusively bone-resorbing multinuclear cells. They differentiate from the monocyte/macrophage lineage of hematopoietic stem cells in the presence of receptor activator for nuclear factor-κB (NF-κB) ligand (RANKL).[4] RANKL plays a key role in the efficiency of osteoclast differentiation and activation. An interaction between RANKL and its receptor, RANK, triggers the recruitment of tumor necrosis factor receptor-associated
factor (TRAF) family proteins. Subsequently, TRAF proteins activate downstream transcription factors, including activation protein-1 (AP-1) and NF-κB, through the mitogen-activated protein (MAP) kinases (ERK [extracellular signal-regulated kinase], JNK [c-Jun N-terminal kinase], and p38) signaling pathway. These RANKL-induced signaling pathways also induce the expression and activation of nuclear factor of activated T cells (NFATc1), which is known to be an essential transcription factor that regulates osteoclast differentiation.

Natural products have been used as sources for the active ingredients in new drug development for treating bone diseases. They have shown a protective effect on bone disease models by inhibiting osteoclastogenesis. Selaginella tamariscina (ST) is a medicinal plant traditionally used for treating the symptoms of blood in the excrement, hematuria, and traumatic bleeding in Korea. Several studies have reported diverse pharmacological effects of ST, including anti-acne, anti-inflammation, and anti-tumor activity. To date, no study has evaluated the inhibitory effect of ST on osteoclast differentiation to examine the potential of ST for treating bone diseases.

This study aimed to investigate Selaginella tamariscina water extract (ST-WE) as an inhibitor of osteoclastogenesis. We had previously used the murine monocyte RAW264.7 cells to screen a library of extracts from traditional medicinal plant. RAW264.7 cells are widely used as an in vitro model for studying osteoclast differentiation. On this preliminary screening, we found that ST-WE strongly inhibited RANKL-induced tartrate-resistant acid phosphatase (TRAP) activity in osteoclasts. In this study, we confirmed the inhibitory effects of ST-WE on RANKL-induced osteoclast differentiation in RAW264.7 cells, and we targeted signaling pathways and relevant transcription factors to elucidate the molecular mechanism underlying ST-WE inhibitory activity.

MATERIALS AND METHODS

Plant material

ST was commercially available and purchased from Baekje herb (Daejeon, Chungnam, Republic of Korea). The voucher specimen (No. G18) was deposited in the herbal bank of the Center for Herbal Medicine Improvement Research, Korea Institute of Oriental Medicine. ST (50.06 g) was placed in 1 l of distilled water and then extracted by heating for 3 hours. After extraction, the ST-WE was filtered out using standard testing sieves (106 μm) (Retsch, Haan, Germany), lyophilized overnight, and stored at 4°C before use. The extraction yield of ST-WE was approximately 5.62% (w/w).

Cell culture and induction of multinucleated osteoclasts

All materials for cell culture were purchased from Gibco (Invitrogen Inc., Carlsbad, CA, USA). RAW264.7 cells (TIB-71) were purchased from ATCC (Manassas, VA, USA) and grown in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin in 5% CO2 at 37°C. The medium was changed every 3 days. For osteoclast differentiation, RAW264.7 cells (1 × 105 cells/well) were cultured in a minimal essential medium (a-MEM) supplemented with 10% FBS and 100 ng/ml RANKL (RandD Systems Inc., Minneapolis, MN, USA). After 3 days, multinucleated osteoclasts were observed.

Cell viability assay

RAW264.7 cells (1 × 105 cells/well) were plated in a 96-well plate in a-MEM containing 10% FBS. After 24 hours, ST-WE was serially diluted and incubated for 3 days. A Cell Counting Kit-8 (Dojindo Molecular Technologies, Rockville, MD, USA) was used to examine cell viability according to the manufacturer’s protocol. Data represented the mean ± SD of triplicate.

Tartrate-resistant acid phosphatase staining and activity assay

Multinucleated osteoclasts were fixed in 10% formalin for 10 minutes and ethanol/acetone (1:1) for 1 minute, then stained using a Leukocyte Acid Phosphatase Kit 387-A (Sigma, St. Louis, MO, USA). The images of TRAP-positive multinucleated cells were captured using a microscope with a DIXI eXcope 5.0 (DIXI Optics Co. Ltd., Daejeon, Republic of Korea). Micrographs of multinucleated osteoclasts were observed at a magnification of 100×.

To measure TRAP activity, multinucleated osteoclasts were fixed in 10% formalin for 10 minutes and 95% ethanol for 1 minute, and then incubated with 100 μl of citrate buffer (50 mM, pH 4.6) containing 10 mM sodium tartrate and 5 mM p-nitrophenylphosphate (Sigma, St. Louis, MO, USA). After incubation for 1 hour at 37°C, the enzyme reaction mixtures were transferred into new plates containing an equal volume of 0.1N NaOH. Absorbance was measured at 410 nm, and TRAP activity was presented as a percentage (%) of the control. The experiment was performed in triplicate.

Primer design and real-time quantitative polymerase chain reaction

Primers were designed using an online primer design program, Primer3. Primer nucleotide sequences used in this study were shown in Table 1. For osteoclast differentiation-related gene expression, RAW264.7 cells (2 × 105 cells/well in a 6-well plate) were treated with RANKL for 3 days, ST-WE was added 1 day after RANKL treatment began, and mRNA expression of
Table 1: Primer sequence used in this study

| Target gene | Forward (5'-3') | Reverse (5'-3') |
|-------------|-----------------|-----------------|
| c-fos       | CCAGTCAAGGAGCATCAGCAA | AAGTAGTGCAGCCCGGAGTA |
| Fra-1       | CAGCCCTATTTCTGGGGACC | CTTTTCCTCGGTCTGCACT |
| Fra-2       | ATCCAGCCTACATCCTCCTAC | GTTTCTCCCTCCGGGATT |
| NFATc1      | GGTTGAGTGTTGAGGGCAAGAT | GAAAGTCAAGAATGGGAGGG |
| TRAP        | ACACAGTGTAGTGGTGTGACACT | CCAGGAGGCTCTCCTATATGGG |
| c-Src       | CCAGGGCTAAGAGCATCAGCAA | GGTCTTGGAGAGTCTTGG |
| Cathepsin K | GGGGCAACTCAAGAAGAAAC | CTGTTGAGGTGGTGTC |
| ATP6v0d2    | AGACCAGGGACTATGGCAAC | CCAGGAGGCTCTCCTATATGGG |
| MMP-9       | GCCACCGTCTCTTCTTGGT | CAGGGGAGGCTCTCCTATATGGG |
| GAPDH       | AACTTCTGCTTATGGGAAGG | ACACATGGGCTCTCCTATATGGG |

Western blot analysis
RAW264.7 cells (2×10^4 cells/well) were plated in a 6-well plate and pre-treated with or without ST-WE for 2 hours, and then stimulated with RANKL (100 ng/ml) for 1 day. Total RNA was isolated with RNeasy mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. First-strand cDNA was synthesized with 2 μg total RNA, 1 μM of oligo-dT_18 primer, 10 units of the RNase inhibitor RNAsin (Promega, Fitchburg, WI, USA), and Omniscript Reverse Transcriptase (Qiagen, Valencia, CA, USA), according to the manufacturer’s protocol. Subsequently, SYBR green-based quantitative polymerase chain reaction (QPCR) amplification was performed using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and the Applied Biosystems 7500 Real-Time PCR System, with first-strand cDNA diluted to 1 : 50 and 20 pmol of primers, according to the manufacturer’s protocol. The PCR reaction consisted of three segments. The first segment was conducted for polymerase activation at 95°C for 10 minutes. The second segment consisted of a three-step cycle run for 40 cycles at 94°C for 40 seconds, 55°C for 40 seconds, and 72°C for 1 minute. The third segment, for the generation of PCR product temperature dissociation curves (melting curves), was run at 95°C for 1 minute, 55°C for 30 seconds, and 95°C for 30 seconds. All reactions were run in triplicate, and data were analyzed using the 2^-ΔΔCT method described previously. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal standard.

Pit formation assay
RAW264.7 cells (1×10^4 cells/well) were seeded into calcium phosphate apatite-coated plates (BioCoat calcium phosphate apatite-coated plates (BioCoat).
Osteologic multitest slides, BD Biosciences, MA, USA) with α-MEM containing 10% FBS and 100 ng/ml RANKL. ST-WE was treated with RANKL every 3 days from the differentiation day 6 at which the mature osteoclasts were almost functionally activated. After 10 days incubation, the slides were washed with 6% sodium hypochlorite solution to remove cells. The resorbed areas on the slides were observed under microscope.

Statistical analysis
SPSS software (SPSS Inc., Chicago, IL, USA) was used to perform all statistical analyses. The significance of TRAP activity was determined using a Student’s t-test. The significance of the mRNA expression levels of osteoclast differentiation-related genes was determined with a Student’s t-test using GAPDH-normalized 2ΔΔCT values. A P value less than 0.05 was considered to be significant.

RESULTS

Selaginella tamariscina water extract inhibited RANKL-induced osteoclast formation in RAW264.7 cells
We first evaluated the effect of ST-WE on RAW264.7 cell viability to exclude any potential cytotoxic effect. No ST-WE concentration used adversely affected cell proliferation [Figure 1a]. Next, we investigated the effect of ST-WE on RANKL-induced osteoclast differentiation in RAW264.7 cells. After 3 days of ST-WE treatment, TRAP activity and multinuclear osteoclast formation were examined. RANKL treatment alone induced formation of TRAP-positive multinuclear osteoclasts in RAW264.7 cells. ST-WE at 200 and 400 μg/ml significantly reduced both RANKL-induced TRAP activity, P<0.01, Figure 1b and multinuclear osteoclast formation [Figure 1c].

Figure 1: Effects of ST-WE on (a) cell growth, (b) RANKL-induced TRAP activity, and (c) RANKL-induced formation of TRAP-positive multinucleated osteoclasts. RAW264.7 cells (1 × 10^5 cells/well in a 96-well plate) were incubated with RANKL (100 ng/ml) and the indicated concentrations of ST-WE for 3 days. Micrographs of multinucleated osteoclasts were shown at a magnification of 100×. Data represented the mean ± SD of triplicate, **P<0.01

Selaginella tamariscina water extract inhibited RANKL-induced mRNA expression of osteoclast differentiation-related genes
RANKL-induced osteoclastogenesis is associated with increased expression of osteoclast differentiation-related genes, including TRAP, c-Src, cathepsin K, the d2 isoform of vacuolar ATPase V(0) domain (ATP6v0d2), and matrix metalloproteinase (MMP)-9. Therefore, we investigated whether ST-WE inhibited the mRNA expression of these five genes by real-time QPCR. RANKL significantly upregulated the mRNA expression of TRAP, c-Src, cathepsin K, ATP6v0d2, and MMP-9 [P<0.05, Table 2]. However, at 400 μg/ml, ST-WE significantly inhibited RANKL-induced expression of TRAP, cathepsin K, and ATP6v0d2 mRNA (P<0.05).

Selaginella tamariscina water extract inhibited RANKL-induced mRNA expression of activation protein-1 and nuclear factor of activated T cells 1
AP-1 and NFATc1 are essential transcription factors that regulate RANKL-induced osteoclastogenic gene expression. Therefore, we explored whether ST-WE inhibited the mRNA expression of AP-1 family members (c-fos, Fra-1, and Fra-2) and NFATc1 by real-time QPCR. The mRNA expression was significantly increased upon RANKL stimulation, but 50 μg/ml of ST-WE significantly decreased RANKL-induced expression of c-fos and NFATc1 mRNA [P<0.05, Table 3]. In addition, ST-WE at 400 μg/ml significantly inhibited the expression of c-fos, Fra-2, and NFATc1 mRNA (P<0.05).

Selaginella tamariscina water extract inhibition of RANKL-induced mitogen-activated protein kinases and NF-κB activation
MAP kinases and NF-κB are the key signaling pathways activated during RANKL-stimulated osteoclastogenesis. To
Table 2: Effects of ST-WE on receptor activator for the nuclear factor-κB ligand-induced mRNA expression of osteoclast differentiation-related genes

| Condition                      | TRAP   | c-Src  | Cathepsin K | ATP6v0d2 | MMP-9   |
|--------------------------------|--------|--------|-------------|----------|---------|
| Without RANKL                  | 1.01 ± 0.18 | 1.05 ± 0.35 | 1.01 ± 0.19 | 1.02 ± 0.27 | 1.08 ± 0.53 |
| With RANKL                     | 1249.28 ± 127.76 | 41.37 ± 11.81 | 2426.69 ± 157.49 | 112.57 ± 4.35 | 1520.06 ± 337.93 |
| RANKL+ST-WE (50 µg/ml)         | 1238.83 ± 100.58 | 35.69 ± 2.12 | 2461.01 ± 103.42 | 87.55 ± 13.79 | 1288.12 ± 113.19 |
| RANKL+ST-WE (400 µg/ml)        | 749.41 ± 110.73 | 39.66 ± 4.42 | 1590.04 ± 333.98 | 85.97 ± 10.15 | 1306.62 ± 217.23 |

ST-WE, Selaginella tamariscina water extract. All mRNA expression was analyzed by quantitative PCR. For osteoclast differentiation-related gene expression, cells were treated with RANKL for 3 days, ST-WE was added 1 day after RANKL treatment began, and mRNA expression of osteoclast differentiation-related genes were evaluated after 3 days of RANKL treatment. Data represented the mean ± SD of triplicate. *p < 0.05, compared to group without RANKL; **p < 0.05, compared to group with RANKL.

Table 3: Effects of ST-WE on receptor activator for the nuclear factor-κB ligand-induced mRNA expression of transcription factors

| Condition                      | c-fos   | Fra-1   | Fra-2   | NFATc1  |
|--------------------------------|---------|---------|---------|---------|
| Without RANKL                  | 1.00 ± 0.07 | 1.01 ± 0.15 | 1.00 ± 0.08 | 1.01 ± 0.10 |
| With RANKL                     | 1.83 ± 0.30 | 2.06 ± 0.61 | 7.42 ± 1.64 | 9.78 ± 1.55 |
| RANKL+ST-WE (50 µg/ml)         | 0.80 ± 0.02 | 2.45 ± 0.35 | 5.04 ± 0.41 | 5.84 ± 0.78 |
| RANKL+ST-WE (400 µg/ml)        | 1.09 ± 0.17 | 2.54 ± 0.29 | 4.10 ± 0.58 | 3.21 ± 0.23 |

ST-WE, Selaginella tamariscina water extract. All mRNA expression was analyzed by quantitative PCR. For transcription factor gene expression, cells were treated with ST-WE 2 hours before RANKL treatment, and mRNA expression of transcription factors were evaluated 1 day after RANKL treatment. Data represented the mean ± SD of triplicate. *p < 0.05, compared to group without RANKL; **p < 0.05, compared to group with RANKL.

determine whether ST-WE affected the activities of these pathways, we explored the activation of MAP kinases, IκBα, and NF-κB p65 by measuring phosphorylation levels using Western blot analysis. Within only 15 minutes after RANKL treatment, the phosphorylation levels of three MAP kinases (ERK, JNK, and p38) had increased [Figure 2]. At later times, phosphorylation of ERK was sustained, but that of JNK and p38 decreased at 30 minutes. In contrast, ST-WE treatment inhibited RANKL-induced phosphorylation of MAP kinases at 15 minutes. In addition, RANKL-induced IκBα phosphorylation was slightly increased at 5 minutes but markedly elevated at 30 minutes [Figure 3]. NF-κB p65 phosphorylation attained a maximal level at 5 minutes and decreased to the basal level at later times. However, ST-WE treatment completely inhibited increase in IκBα phosphorylation to level that was below the basal level of ST-WE-free control at 30 minutes. In addition, ST-WE treatment also inhibited increase in NF-κB p65 phosphorylation to level that was half of maximal level of ST-WE-free control at 5 minutes.

**Selaginella tamariscina** water extract inhibited RANKL-induced pit formation

We used a pit formation assay to further explore the inhibitory effect of ST-WE on bone resorption by osteoclasts. RAW264.7 cells were incubated on calcium phosphate apatite-coated plates with RANKL for 6 days and next treated with ST-WE for a further 10 days. RANKL treatment increased the pit formation compared with that of cells cultured in the absence of RANKL. ST-WE markedly inhibited RANKL-induced pit formation [Figure 4].

**DISCUSSION**

RANKL binding to its receptor results in phosphorylation of MAP kinases, which are proline-directed serine/threonine kinases that transmit RANKL signals to the nucleus during osteoclast differentiation.[11] AP-1, composed of the Jun and Fos proteins, has been identified as a target of MAP kinase-signaling pathway. Each activated MAP kinase plays a distinct role in the osteoclastogenic signaling pathway. p38 stimulates osteoclast differentiation, which is reciprocally controlled by ERK.[13] In parallel, JNK activation is required to induce AP-1 expression and activation, particularly that of c-Jun and JunD, which in turn regulates NFATc1 expression.[14,15] After initial expression induced by RANKL stimulation, NFATc1 and AP-1 cooperatively trigger amplification of NFATc1.[16,17] Next, AP-1 and NFAT form transcription complex that bind to regulatory sites on the promoters of osteoclast differentiation-related genes, including TRAP, cathepsin K, and ATP6v0d2, to regulate gene expression.[17-20] Therefore, ST-WE inhibition of MAP kinases [Figure 2], followed by suppression of AP-1 (c-fos and Fra-2) and NFATc1 expression [Table 3], may inhibit osteoclastogenesis by blocking osteoclastogenic gene transcription.

The transcription factor NF-κB is composed of homo- or hetero-dimers of NF-κB family members, Rel-A/
In the canonical NF-κB pathway, interaction between RANKL and RANK activates the I-κB kinase complex, which, in turn phosphorylates NF-κB-associated I-κB, leading to ubiquitination and degradation of I-κB. The NF-κB dimers, mostly p50 and Rel-A, are sequentially released and translocated into nucleus to regulate gene transcription. Osteoclast precursor cells deficient in I-κBα phosphorylation fail to form multinuclear osteoclasts and decrease bone resorption activity. In addition, osteoclast precursor cells from RelA⁻/⁻Tnfr1⁻/⁻ mice show an increased level of cell death that prevents effective RANKL-induced osteoclastogenesis. Interestingly, p38 mediates NFATc1 expression through phosphorylation of NF-κB p65 (Rel-A), which in turn increases the transactivation activity of NF-κB. Cells from “knock-in” mice expressing the unphosphorylated form of NF-κB p65 show a dramatic reduction in NF-κB transcriptional activity. Phosphorylation of NF-κB p65 is also required for association of NF-κB with either CBP/p300 or HDAC, to mediate an efficient transcription. Therefore, the inhibitory effect of ST-WE on RANKL-induced phosphorylation of I-κBα and NF-κB p65 (Figure 3) may inhibit the NF-κB signaling pathway, in turn inhibiting efficient transcription of genes involved in osteoclastogenesis.

RANKL signaling modulates the expression of osteoclast differentiation-related genes (TRAP, cathepsin K, and ATP6v0d2) through NFAT and AP-1 activity in their promoter regions. As mRNA expression of TRAP, cathepsin K, and ATP6v0d2 increases during osteoclast differentiation, TRAP, cathepsin K, and ATP6v0d2 participate in the bone resorption function of osteoclasts. We found that ST-WE inhibited both mRNA expression of these genes (Table 2) and bone resorption activity (Figure 4). This suggests that ST-WE inhibition of the expression of osteoclast differentiation-related genes might block the bone resorption activity of osteoclasts.

ST contains a large number of active compounds, including a biflavonoid. Although biflavonoids from Cephalotaxus koreana stimulate osteoblast differentiation, no study has...
yet addressed the inhibitory effects of biflavonoids or ST-WE on osteoclast differentiation.\(^{[3]}\) In the present study, we found that ST-WE inhibited RANKL-induced MAP kinases, NF-κB activation [Figures 2 and 3], and mRNA expression of transcription factors [Table 3] that are crucial for osteoclast differentiation. Further study is required to determine whether a biflavonoid may be the active ST-WE component that inhibits RANKL-induced osteoclastogenesis.

In conclusion, we showed that ST-WE significantly reduced RANKL-induced osteoclastogenesis by inhibiting the activation of signaling molecules and the expression of relevant transcription factors. These results suggest that ST-WE may have beneficial effects on bone-destructive disease by inhibiting osteoclastogenesis and the activity of osteoclasts. Further studies are required to identify the active components of ST-WE and to evaluate their efficacies in vivo.

**ACKNOWLEDGMENTS**

We thank Sung-Up Choi (Korea Institute of Oriental Medicine) for critical reading of the manuscript. This work was supported by a grant from the Korea Institute of Oriental Medicine (D110040), Ministry of Knowledge Economy, Republic of Korea.

**REFERENCES**

1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
2. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289:1504-8.
3. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-14.
4. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007;7:292-304.
5. Putnam SE, Scott AM, Bicknell K, Priestley CM, Williamson EM. Natural products as alternative treatments for metabolic bone disorders and for maintenance of bone health. Phytother Res 2007;21:99-112.
6. Kim JW, Shin DI. Flavonoid constituents of Selaginella tamariscina. Kor J Pharmacogn 1991;22:207-10.
7. Joo SS, Jang SK, Kim SG, Choi JS, Hwang KW, Lee do I. Anti-acute activity of Selaginella involvens extract and its non-antibiotic antimicrobial potential on Propionibacterium acnes. Phytother Res 2008;22:335-9.
8. Kuo YC, Sun CM, Tsai WJ, Ou JC, Chen WP, Lin CY. Chinese herbs as modulators of human mesangial cell proliferation: preliminary studies. J Lab Clin Med 1998;132:76-85.
9. Lee IS, Nishikawa A, Furukawa F, Kasahara K, Kim SU. Effects of Selaginella tamariscina on in vitro tumor cell growth, p53 expression, G1 arrest and in vivo gastric cell proliferation. Cancer Lett 1999;144:93-9.
10. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombo A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96:3540-5.
11. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000;132:365-86.
12. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-\(^{ΔΔ}\)CT method. Methods 2001;25:402-8.
13. Hotokezaka H, Sakai E, Kanaoka K, Saito K, Matsuo K, Kitaura H, et al. UO126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 2002;277:47366-72.
14. Srivastava S, Weitzmann MN, Cenci S, Ross FP, Adler S, Pacifici R. Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J Clin Invest 1999;104:503-13.
15. David JP, Sabapathy K, Hoffmann O, Idarraga MH, Wagner EF. JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci 2002;115:4317-25.
16. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005;202:1261-9.
17. Reddy SV, Hundley JE, Windle JJ, Alcantara O, Linn R, Leach RJ, et al. Characterization of the mouse tartrate-resistant acid phosphatase (TRAP) gene promoter. J Bone Miner Res 1995;10:601-6.
18. Kim K, Lee SH, Ha Kim J, Choi Y, Kim N. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP). Mol Endocrinol 2008;22:176-85.
19. Pang M, Martinez AF, Fernandez I, Balkan W, Troen BR. AP-1 stimulates the cathepsin K promoter in RAW 264.7 cells. Gene 2007;15:151-8.
20. Song I, Kim JH, Kim K, Jin HM, Youn BU, Kim N. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. FEBS Lett 2009;583:2435-40.
21. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev 2004;18:2195-224.
22. Abu-Amer Y, Dowdy SF, Ross FP, Clohisy JC, Teitelbaum SL. LAT fusion proteins containing tyrosine 42-deleted IkappaBalpalpha arrest osteoclastogenesis. J Biol Chem 2001;276:30499-503.
23. Vaira S, Alahwargi M, Anwisye I, Kitaura H, Faccio R, Novack DV. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest 2008;118:2088-97.
24. Huang H, Ryu J, Ha J, Chang EJ, Kim HJ, Kim HM, et al. Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-kappaB transactivation by RANKL. Cell Death Differ 2006;13:1879-91.
25. Dong J, Jimi E, Zhong H, Hayden MS, Ghosh S. Repression of gene expression by unphosphorylated NF-κB p65 through epigenetic mechanisms. Genes Dev 2008;22:1159-73.
26. Sundaram K, Nishimura R, Senn J, Youssef RF, London SD, Reddy SV. RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation. Exp Cell Res 2007;313:168-78.
27. Halleen JM, Raisanen S, Salo JJ, Reddy SV, Roodman GD, Hentunen TA, et al. Intracellular fragmentation of bone resorption products by reactive oxygen species generated by osteoclastic tartrate-resistant acid phosphatase. J Biol Chem 1999;274:22907-10.
28. Saffig P, Hunziker E, Everts V, Jones S, Boyd A, Wehmeyer O,
et al. Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice. Adv Exp Med Biol 2000;477:293-303.

29. Wu H, Xu G, Li YP. ATP6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption. J Bone Miner Res 2009;24:871-85.

30. Okigawa M, Hwa CW, Kawano N, Rahman W. Biflavones in Selaginella species. Phytochemistry 1971;10:3286-7.

31. Lee MK, Lim SW, Yang H, Sung SH, Lee HS, Park MJ, et al. Osteoblast differentiation stimulating activity of biflavonoids from Cephalotaxus koreana. Bioorg Med Chem Lett 2006;16:2850-4.

Cite this article as: Shim K, Kang J, Lee M, Ma JY. Selaginella tamariscina water extract inhibits receptor activator for the nuclear factor-κB ligand-induced osteoclast differentiation by blocking mitogen-activated protein kinase and NF-κB signaling. Phcog Mag 2012;8:184-91.

Source of Support: Grant from the Korea Institute of Oriental Medicine (D10040), Ministry of Knowledge Economy, Republic of Korea, Conflict of Interest: None declared.